Skip to main content.

Jesus Gonzalez Lugo, M.D.

Jesus Gonzalez Lugo portrait
Assistant Professor, Hematologic Malignancies and Cellular Therapeutics
jgonzalezlugo@kumc.edu

Professional Background

Dr. Gonzalez Lugo completed his Internal Medicine Residency at Albert Einstein College of Medicine. He proceeded to complete his Hematology and Oncology Fellowship at Montefiore Medical Center, Albert Einstein College of Medicine, where he also served as chief fellow. His clinical and research interests include Myelodysplastic Syndromes and Acute Leukemias.

Education and Training
  • MD, Doctor of Medicine, Universidad de Monterrey, Monterrey, Mexico
  • Residency, Internal Medicine, Jacobi Medical Center/ Albert Einstein College of Medicine, Bronx, New York
  • Clinical Fellowship, Hematology and Medical Oncology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, New York
Professional Affiliations
  • American Society of Clinical Oncology, Member, 2018 - Present
  • American Society of Hematology, Member, 2018 - Present

Publications
  • Thakkar, A, Gonzalez-Lugo, J., D, Goradia, N, Gali, R, Shapiro, L., C, Pradhan, K, Rahman, S, Kim, S., Y, Ko, B, Sica, R., A, Kornblum, N, Bachier-Rodriguez, L, McCort, M, Goel, S, Perez-Soler, R, Packer, S, Sparano, J, Gartrell, B, Makower, D, Goldstein, Y., D, Wolgast, L, Verma, A, Halmos, B. 2021. Seroconversion rates following COVID-19 vaccination among patients with cancer.. Cancer cell, 39 (8), 1081-1090.e2
  • Billett, H., H, Reyes-Gil, M, Szymanski, J, Ikemura, K, Stahl, L., R, Lo , Y, Rahman, S, Gonzalez-Lugo, J., D, Kushnir, M, Barouqa, M, Golestaneh, L, Bellin, E. 2020. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.. Thrombosis and haemostasis, 120 (12), 1691-1699
  • Shastri, A, Gonzalez-Lugo, J, Verma, A. 2020. Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies.. Blood cancer discovery, 2 (2), 113-115
  • Gonzalez-Lugo, J., D, Chakraborty, S, Verma, A, Shastri, A. 2021. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.. Seminars in hematology, 58 (1), 56-65
  • Gonzalez-Lugo, J., D, Kambhampati, S, Yacoub, A, Donnellan, W., B, Berdeja, J, Bhagat, P, Fehn, K, Remy, C, Jasra, S, Kazemi, M, Pradhan, K, Kim, M, Mantzaris, I, Sica, R., A, Shah, N, Goldfinger, M, Kornblum, N, Gritsman, K, Braunschweig, I, Steidl, U, Will, B, Shastri, A, Verma, A. 2022. Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.. Clinical Cancer Research